Anemia in head and neck cancers;Anémie et cancers des voies aérodigestives supérieures

Bulletin du Cancer

Volumn 92, Issue 5, 2005, Pages 445-451

  Azria, David ^a   Zouhair, Abderrahim ^b   Serre, Antoine ^a   Lemanski, Claire ^a   Schneider, Maurice ^c   Ozsahin, Mahmut ^b   Dubois, Jean Bernard ^a   Lartigau, Éric ^d  

^a CENTRE VAL D AURELLE   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d CENTRE OSCAR LAMBRET   (France)

Author keywords

Anemia; Erythropoietin; Head and neck cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; NIMORAZOLE; RECOMBINANT ERYTHROPOIETIN; HEMOGLOBIN A;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL ACTIVATION; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; MALE; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; CELL HYPOXIA; HEAD AND NECK TUMOR; MORTALITY; QUALITY OF LIFE; REVIEW;

ANEMIA; BLOOD TRANSFUSION; CELL HYPOXIA; ERYTHROPOIETIN, RECOMBINANT; HEAD AND NECK NEOPLASMS; HEMOGLOBIN A; HUMANS; PROGNOSIS; QUALITY OF LIFE;

EID: 20344370521     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25 (suppl. 7): 2-6.
2. Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist 2000; 5 (suppl. 2): 13-8.
3. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95: 1650-9.
4. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25 (suppl. 7): 43-6.
5. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001; 28 (suppl. 8): 7-14.
6. Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998; 41: 347-53.
7. Overgaard J, Hansen HS, Jorgensen K, Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma: an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1986; 12: 515-21.
8. Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998; 42: 1069-75.
9. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-49.
10. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
11. Vaupel P, Thews O, Kelleher DK, Hoeckel M. Oxygenation of human tumors: the Mainz experience. Strahlenther Onkol 1998; 174 (suppl. 4): 6-12.
12. Lartigau E, Le Ridant AM, Lambin P, Weeger P, Martin L, Sigal R, et al. Oxygenation of head and neck tumors. Cancer 1993; 71: 2319-25.
13. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz IR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-3.
14. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
15. Russo CA, Weber TK, Volpe CM, Srolet DL, Petrelli NJ, Rodriguez-Bigas M, et al. An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res 1995; 55: 1122-8.
16. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
17. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
18. Pasquier D, Larcigau E. Anémie et radiothérapie. Bell Cancer 2003; 90: 152-7.
19. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95: 7987-92.
20. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and rumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-9.
21. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31-9.
22. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14: 831-8.
23. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-9.
24. Cygler J, Klassen NV, Ross CK, Bichay TJ, Raaphorst GP. The survival of aerobic and anoxic human glioma and melanoma cells after irradiation at ultrahigh and clinical dose rates. Radiat Res 1994; 140: 79-84.
25. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9.
26. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
27. Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 1998; 58: 3547-50.
28. Horsman MR. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998; 42: 701-4.
29. 2) during accelerated radiotherapy of head and neck carcinoma. Eur J Cancer 1998; 34: 856-61.
30. Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 459-66.
31. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989; 16: 1065-8.
32. Fazekas JT, Scott C, Marcial V, Davis LW, Wasserman T, Cooper JS. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79-15. Int J Radiat Oncol Biol Phys 1989; 17: 1177-81.
33. Bentzen SM, Johansen LV, Overgaard J, Thames HD. Clinical radiobiology of squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 1991; 20: 1197-206.
34. Bryne M, Eide GE, Lilleng R, Langmark F, Thrane PS, Dabelsteen E. A multivariate study of the prognosis of oral squamous cell carcinomas. Are blood group and hemoglobin new prognostic factors? Cancer 1991; 68: 1994-8.
35. Van Achr MJ, Hermans J, Boks DE, Leer JW. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992; 23: 229-35.
36. Grant DG, Hussain A, Hurman D. Pre-tteatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 1999; 113: 829-33.
37. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran Jr WJ, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic laryn. J Clin Oncol 1995; 13: 2077-83.
38. Tarnawski R, Skladowski K, Madejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys 1997; 38: 1007-11.
39. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996; 201: 553-8.
40. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
41. Zouhair A, Azria D, Pasche P, Stupp R, Chevalier J, Betz M, et al. Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer. Radiother Oncol 2004; 70: 183-8.
42. Ozsahin M, Pasche P, Lurhi F, Azria D, Betz M, Matzinger O, et al. Decrease in the hemoglobin level influences the outcome in head and neck patients treated with postoperative accelerated radiation therapy. Proc Am Soc Ther Radiat Oncol 2004; 60 (abstr. 2289).
43. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: Dahanca 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-40.
44. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (Dahanca) Protocol 5-85. Radiother Oncol 1998; 46: 135-46.
45. Littlewood TJ, Cella D, Nortier JW. Erythropoietin improves quality of life. Lancet Oncol 2002; 3: 459-60.
46. Iconomou G, Kontras A, Rigopoulos A, Vagenakis AG, Kalofonos HP. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. J Pain Symptom Manage 2003; 25: 512-8.
47. Kelleher DK, Thews O, Vaupel P. Can erythropoietin improve tumor oxygenation? Strahlenther Onkol 1998; 174 (suppl. 4): 20-3.
48. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. Cancer 1999; 86: 1362-7.
49. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9: 255-60.
50. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204-14.
51. Quirt I, Micucci S, Moran LA, Pater J, Browman G. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. Cancer Prev Control 1997; 1: 241-8.
52. Scorr SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study. Laryngoscope 2002; 112: 1221-9.
53. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561-5.
54. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al. Eryrhropoierin regulates tumour growth of human malignancie. Carcinogenesis 2003; 24: 1021-9.
55. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients wirh anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
56. Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell F, Jolliffe L, et al. Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res 2003; 63: 6162-5.
57. Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 1999; 50: 185-90.
58. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-15.
59. Lartigau E, Denis F. Commentaires de l'article de M. Henke: "Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double blind, placebo controlled trial" or how a cytokine remains a cytokine. Cancer Radiother 2004; 8: 131-3.
60. Spaeth D, Casadevall N, Daouphars M, Marchal C, Marec-Berard P, Fabre N, et al. Recommandations pour la pratique clinique: Standards, Options et Recommandations 2003 pour l'utilisation de l'érythropoïétine recombinante (époetine alfa et bêta, darbepoetine alfa, EPO) dam la prise en charge de l'anémie en cancérologie, mise à pur (rapport intégral). Paris: John Libbey Eurotext, 2003.
61. Machtay M, Pajak T, Suntharalingam M, Hershock D, Stripp DC, Cmelak A, et al. Definitive radiotherapy ± erythropoietin for squamous cell carcinoma of the Head and Neck: Preliminary report of RTOG 9903. Proc Am Soc Ther Radiat Oncol 2004; 60 (abstr. 5).